SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Zacks11-21

Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485125830?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QsgmBPisi3OOmQsNZTidNg--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/048cb98376b33bd6dcff462577373727","is_english":true,"pubTime":"2024-11-21 00:04","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485125830","market":"us","top_or_hot":-1,"title":"SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels","media":"Zacks","content":"<div>\n<p>Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sln-stock-down-despite-cholesterol-160400416.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 00:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/sln-stock-down-despite-cholesterol-160400416.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/sln-stock-down-despite-cholesterol-160400416.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001440.SGD","symbol_name":"United Global Dividend Equity Fund A SGD Dist","start_time":0,"source_url":"https://finance.yahoo.com/news/sln-stock-down-despite-cholesterol-160400416.html","article_id":"2485125830","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QsgmBPisi3OOmQsNZTidNg--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/048cb98376b33bd6dcff462577373727"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485125830","pubTimestamp":1732118640,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The results from the phase II ALPACAR-360 study of zerlasiran for the ASCVD indication were presented at a medical conference in Chicago, IL, and simultaneously published in the Journal of the American Medical Association.Per the data readout, zerlasiran, administered at doses of 300 mg every 16 or 24 weeks or 450 mg every 24 weeks, achieved more than 80% mean time-averaged placebo-adjusted reductions in Lp levels over 36 weeks, with maximum reductions surpassing 90%. At the final follow-up, 60 weeks after the initial dose, Lp reductions were sustained, and the treatment remained safe with infrequent dosing.However, it was also observed that Lp reduction levels with zerlasiran in the ALPACAR-360 study declined between the 16 weeks and 24 weeks 300mg doses, signifying diminishing efficacy. This has raised questions regarding the competitive profile of the drug compared to a therapeutic candidate being developed by Amgen AMGN for the same indication.Year to date, shares of Silence Therap","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4505":"高瓴资本持仓","BK4550":"红杉资本持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4568":"美国抗疫概念","BK4581":"高盛持仓","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4566":"资本集团","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","PFE":"辉瑞","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SLN":"Silence Therapeutics Plc","AMGN":"安进","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4592":"伊斯兰概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4599":"减肥药","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4585":"ETF&股票定投概念","SG9999002232.USD":"Allianz Global High Payout USD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4007":"制药","ALLO":"Allogene Therapeutics Inc.","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4588":"碎股","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"尽管胆固醇药物降低脂蛋白水平，SLN库存仍下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"SLN":1,"PFE":1,"ALLO":1},"content_text":"Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) or Lp(a), a key genetic risk factor for cardiovascular disease. The stock price drop is likely due to investors’ skepticism regarding the effectiveness of the candidate compared to other treatments being developed for the same indication.\nThe results from the phase II ALPACAR-360 study of zerlasiran for the ASCVD indication were presented at a medical conference in Chicago, IL, and simultaneously published in the Journal of the American Medical Association.\nPer the data readout, zerlasiran, administered at doses of 300 mg every 16 or 24 weeks or 450 mg every 24 weeks, achieved more than 80% mean time-averaged placebo-adjusted reductions in Lp(a) levels over 36 weeks, with maximum reductions surpassing 90%. At the final follow-up, 60 weeks after the initial dose, Lp(a) reductions were sustained, and the treatment remained safe with infrequent dosing.\nHowever, it was also observed that Lp(a) reduction levels with zerlasiran in the ALPACAR-360 study declined between the 16 weeks and 24 weeks 300mg doses, signifying diminishing efficacy. This has raised questions regarding the competitive profile of the drug compared to a therapeutic candidate being developed by Amgen AMGN for the same indication.\nYear to date, shares of Silence Therapeutics have plunged 59.9% compared with the industry’s 6.9% decline.\nImage Source: Zacks Investment Research\nSLN Competes With Amgen in the ASCVD Market\nAmgen is also currently evaluating a potentially best-in-class siRNA molecule, olpasiran, for reducing Lp(a) synthesis in ASCVD patients in a late-stage cardiovascular outcomes study. Last year, Amgen reported final data from the phase II OCEAN(a)-DOSE study of the candidate for the ASCVD indication.\nDuring the off-treatment extension period, olpasiran demonstrated a lasting impact on Lp(a) levels, maintaining a 40-50% placebo-adjusted reduction nearly a year after the last dose. In 2022, Amgen reported that doses of olpasiran ≥75 mg, administered every 12 weeks, reduced Lp(a) by more than 95% at week 36. No new safety concerns emerged during the off-treatment phase.\nSilence Therapeutics believes that at least 20% of the global population is affected by elevated Lp(a) levels, which is a major cause of morbidity and mortality in ASCVD patients. Based on the mid-stage study results, Silence Therapeutics is currently analyzing available information to select the best dose and dosing interval for future late-stage studies of zerlasiran to treat ASCVD patients with high Lp(a).\nApart from zerlasiran, Silence Therapeutics has another clinical-stage candidate, divesiran, in its pipeline which is being evaluated in a phase I/II study for polycythemia vera.\n\nSilence Therapeutics PLC Sponsored ADR Price and Consensus\n\nSilence Therapeutics PLC Sponsored ADR price-consensus-chart | Silence Therapeutics PLC Sponsored ADR Quote\n\nSLN’s Zacks Rank and Stocks to Consider\nSilence Therapeutics currently carries a Zacks Rank #3 (Hold).\nSome better-ranked pharma stocks are Allogene Therapeutics ALLO and Pfizer PFE, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nOver the past 60 days, Allogene Therapeutics’ estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost 34% year to date.\nAllogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.\nOver the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.85 to $2.92. PFE shares have lost 12.8% year to date.\nPfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nSilence Therapeutics PLC Sponsored ADR (SLN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485125830"}